Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America.


Journal

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628

Informations de publication

Date de publication:
03 2019
Historique:
received: 15 08 2018
accepted: 28 09 2018
pubmed: 9 10 2018
medline: 29 1 2020
entrez: 9 10 2018
Statut: ppublish

Résumé

Understanding the socioeconomic impact of chronic graft-versus-host disease (GVHD) on affected patients is essential to help improve their overall well-being. Using data from the Chronic GVHD Consortium, we describe the insurance, employment, and financial challenges faced by these patients and the factors associated with the ability to work/attend school and associated financial burdens. A 15-item cross-sectional questionnaire designed to measure financial concerns, income, employment, and insurance was completed by 190 patients (response rate, 68%; 10 centers) enrolled on a multicenter Chronic GVHD Consortium Response Measures Validation Study. Multivariable logistic regression models examined the factors associated with financial burden and ability to work/attend school. The median age of respondents was 56years, and 87% of the patients were white. A higher proportion of nonrespondents had lower income before hematopoietic cell transplantation and less than a college degree. All but 1 patient had insurance, 34% had faced delayed/denied insurance coverage for chronic GVHD treatments, and 66% reported a financial burden. Patients with a financial burden had greater depression/anxiety and difficulty sleeping. Nonwhite race, lower mental functioning, and lower activity score were associated with a greater likelihood of financial burden. Younger age, early risk disease, and higher mental functioning were associated with a greater likelihood of being able to work/attend school. In this multicenter cohort of patients with chronic GVHD, significant negative effects on finances were observed even with health insurance coverage. Future research should investigate potential interventions to provide optimal and affordable care to at-risk patients and prevent long-term adverse financial outcomes in this vulnerable group.

Identifiants

pubmed: 30296479
pii: S1083-8791(18)30607-4
doi: 10.1016/j.bbmt.2018.09.040
pmc: PMC6445749
mid: NIHMS1508939
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

599-605

Subventions

Organisme : NCI NIH HHS
ID : R01 CA118953
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA118953
Pays : United States

Informations de copyright

Copyright © 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Références

J Oncol Pract. 2015 Jan;11(1):12-8
pubmed: 25316026
Psychooncology. 2013 Apr;22(4):911-21
pubmed: 22605430
Biol Blood Marrow Transplant. 2017 Aug;23(8):1387-1392
pubmed: 28412517
Med Care. 1993 Mar;31(3):247-63
pubmed: 8450681
J Cancer Surviv. 2016 Dec;10(6):1104-1111
pubmed: 27277896
J Clin Oncol. 2012 Oct 20;30(30):3746-51
pubmed: 23008296
J Oncol Pract. 2016 Jul;12(7):e755-64
pubmed: 27328795
J Clin Oncol. 2014 Feb 1;32(4):306-11
pubmed: 24366936
J Oncol Pract. 2014 Sep;10(5):332-8
pubmed: 24865220
Biol Blood Marrow Transplant. 2012 Nov;18(11):1620-8
pubmed: 22484549
Cancer. 2010 Jul 15;116(14):3493-504
pubmed: 20549763
Haematologica. 2018 Sep;103(9):1535-1541
pubmed: 29858386
Biol Blood Marrow Transplant. 2011 Jul;17(7):995-1003
pubmed: 21145404
Blood. 2011 Apr 28;117(17):4651-7
pubmed: 21355084
Biol Blood Marrow Transplant. 2002;8(8):444-52
pubmed: 12234170
Blood. 2007 Nov 15;110(10):3784-92
pubmed: 17671231
Cancer. 2013 Oct 15;119(20):3710-7
pubmed: 23907958
Biol Blood Marrow Transplant. 2016 Aug;22(8):1504-1510
pubmed: 27184627
Cancer. 2017 Feb 1;123(3):476-484
pubmed: 27716900
J Support Oncol. 2008 Apr;6(4):183-92
pubmed: 18491687
Oncologist. 2013;18(4):381-90
pubmed: 23442307
Gynecol Oncol. 2012 Mar;124(3):437-43
pubmed: 22138013
J Clin Oncol. 2018 Feb 10;36(5):476-482
pubmed: 29261440
JAMA Oncol. 2017 Jun 1;3(6):757-765
pubmed: 27893028
J Clin Oncol. 2012 May 10;30(14):1608-14
pubmed: 22412136
Biol Blood Marrow Transplant. 2018 Aug;24(8):1727-1732
pubmed: 29476954
Bone Marrow Transplant. 2013 Jun;48(6):865-71
pubmed: 23222378
Biol Blood Marrow Transplant. 2014 Sep;20(9):1375-81
pubmed: 24867778
J Clin Oncol. 2014 Apr 20;32(12):1269-76
pubmed: 24663041
Psychooncology. 2013 Apr;22(4):745-55
pubmed: 22411485

Auteurs

Nandita Khera (N)

Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, Arizona. Electronic address: khera.nandita@mayo.edu.

Betty K Hamilton (BK)

Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.

Joseph A Pidala (JA)

Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

William A Wood (WA)

Division of Hematology/Oncology, University of North Carolina, Chapel Hill, North Carolina.

Vicky Wu (V)

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Jenna Voutsinas (J)

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Lynn Onstad (L)

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Amin M Alousi (AM)

The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Raewyn Broady (R)

Leukemia/Bone Marrow Transplant Program of British Columbia, BC Cancer Agency, Vancouver, British Columbia, Canada.

George L Chen (GL)

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

Mukta Arora (M)

Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.

Corey Cutler (C)

Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Mary E Flowers (ME)

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Alex Ganetsky (A)

Hematology/BMT, University of Pennsylvania, Philadelphia, Pennsylvania.

Madan Jagasia (M)

Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

Philip L McCarthy (PL)

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

Stefanie Sarantopoulos (S)

Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University, Durham, North Carolina.

Gregory A Abel (GA)

Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Navneet S Majhail (NS)

Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.

Stephanie J Lee (SJ)

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH